Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 5/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
| ▸ | PTGFR | P43088 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1147246 | 0.82 | CYP2C19 (0.41) | POLBCYP2C19HIF1ALMNAKMT2A | |
| SCHEMBL6464415 | 0.80 | CYP2C19 (0.56) | CYP2C19HIF1AKMT2AALDH1A1 | |
| SCHEMBL6647551 | 0.80 | CYP2C19 (0.56) | CYP2C19HIF1AKMT2AALDH1A1 | |
| SCHEMBL27823794 | 0.80 | CYP2C19 (0.56) | CYP2C19HIF1AKMT2AALDH1A1 | |
| SCHEMBL30040484 | 0.79 | POLB (0.50) | POLBSMN1; SMN2CYP2C19HIF1ACTSD | |
| SCHEMBL6892090 | 0.79 | POLB (0.50) | POLBSMN1; SMN2CYP2C19HIF1ACTSD | |
| SCHEMBL21656314 | 0.76 | GAA (0.42) | POLBSMN1; SMN2CTSDLMNAMEN1 | |
| SCHEMBL1147825 | 0.75 | CA1 (0.44) | SMN1; SMN2CYP2C19HIF1ALMNAMEN1 | |
| SCHEMBL6946381 | 0.75 | CYP2C19 (0.46) | SMN1; SMN2CYP2C19HIF1ALMNAKMT2A | |
| SCHEMBL21632008 | 0.74 | CYP2C19 (0.49) | POLBSMN1; SMN2CYP2C19HIF1ACTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262005-A1 | Uracil-Type Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Related Thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2005113516-A1 | URACIL-TYPE GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262005-A1 | Uracil-Type Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Related Thereto | GNRHR, FSHR, GHRHR | POLB 635/4885SMN1; SMN2 3355/4885CYP2C19 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.